AUTHORITY

42 U.S.C. 284(c)(3), section 405(c)(3) of the Public Health Act, as amended. The Board has been established in accordance with the Federal Advisory Committee Act, as amended (5 U.S.C. app.), which sets forth standards for the formation and use of advisory committees.

MEMBERSHIP AND DESIGNATION

The Board will consist of up to thirty members, including the Chair, appointed by the Director, NCI, from authorities knowledgeable in the fields of laboratory, clinical and biometric research; clinical cancer treatment; cancer etiology; and cancer prevention and control with emphasis on training and experience in the various disciplines and fields related to scientific areas relevant to carcinogenesis; cancer biology and diagnosis; cancer chemotherapy; cancer epidemiology, cancer education; cancer information services; biological, chemical and physical carcinogenesis; DNA repair; tumor biology and immunology; humoral and cellular immunity; hematopoiesis; cell differentiation and transformation; oncogenes and growth factors; cell signaling; molecular and structural biology; genetic regulation; genetics; genomics; proteomics; viral oncology; vaccine development; transplantation; chemotherapy; pharmacology; drug development and developmental therapeutics; genetic and immunotherapies; pathology; diagnostic research and cytogenetics; biological response modifiers; imaging; survey research; biostatistics; psychology and behavioral medicine; public health and community oncology; cancer detection and diagnosis; cancer treatment and restorative care; nutrition; education of health professionals; medical oncology; gynecologic oncology; and pediatric oncology.

Members will be invited to serve for overlapping terms of up to five years. All non-Federal members of this Board serve as Special Government Employees. A member will serve after the expiration of that member’s term until a successor has taken office. A quorum for the conduct of business by the full Board will consist of 10 members.
DESCRIPTION OF DUTIES

The Board of Scientific Counselors for Basic Sciences, NCI, will review and evaluate the intramural program. This will involve the evaluation of the performance and productivity of tenured and tenure-track principal investigators, senior scientists, and senior clinicians through periodic site visits to intramural Laboratories/Programs of the NCI Center for Cancer Research (CCR).

The site visit review teams, which include at least two Board members, will be provided with a written description of the overall research to be reviewed. This written description will present the overall past accomplishments of the laboratories and their investigators since the last review was conducted. The written description will also present: the general aims, objectives and projected directions of the research to be conducted; appropriate background information on possible future research projects; a brief summary of the general research plan; and an indication of the importance of the research projects to their specific clinical and scientific disciplines. The site visit team, after conducting the review, will prepare a written description and evaluation of the research. This written report will be submitted to the Director, CCR, NCI who will transmit it to the Director, NCI; the Deputy Director for Intramural Research, NIH; and the Director, NIH. The Board will discuss each site visit review and make final recommendations to the CCR Director regarding resources and future course of each research program. These final recommendations shall also be transmitted to the NCI Director, the NIH Deputy Director for Intramural Research, and the NIH Director. The NCI will provide annually to the National Cancer Advisory Board a written description of the research reviewed and the results of each review.

ESTIMATED NUMBER AND FREQUENCY OF MEETINGS

Meetings of the full Board will be held approximately 3 times within a fiscal year. Meetings will be open to the public except as determined otherwise by the Secretary of Health and Human Services (Secretary) in accordance with the subsection (c) of section 552b of Title 5 U.S.C. Notice of all meetings will be given to the public. In the event a portion of a meeting is closed to the public, as determined by the Secretary, in accordance with the Government in the Sunshine Act (5 U.S.C. 552b(c)) and the Federal Advisory Committee Act, a report will be prepared which will contain, as a minimum, a list of members and their business addresses, the Board’s functions, the dates and places of meetings, and a summary of the Board’s activities and recommendations made during the fiscal year. A copy of the report will be provided to the Department Committee Management Officer.